Advancing the Next Wave of Immunotherapy

2024 Annual Report of the Cancer Research Institute

The Cancer Research Institute (CRI) is driving the future of cancer care through immunotherapy, with a strategic focus on People, Biology, and Data. In fiscal year 2024, CRI invested $22.8M in cutting-edge research across seven countries, awarding 64 new grants to fuel discovery in clinical trials, postdoctoral fellowships, and technological advancements. With immunotherapy now available for 29 types of cancer, offering hope to 9M newly diagnosed patients worldwide, this investment is making a real impact. Committed to financial stewardship, CRI directs 83% of expenditures to research and patient education, ensuring every dollar advances its mission. Explore the full report for a closer look at our progress.

Highlights

• From CRI’s Leadership
• CRI’s 2024 Funding Programs
• Significant 2024 Achievements and Collaborations
• Financial Highlights
• Donor Listing
• Governance and Guidance